One of the main symptoms of Autism Spectrum Conditions (ASC) is experiencing cognitive inflexibility when adjustments of behaviour are required. While this so-called behavioural rigidity is broadly recognised in ASC, finding evidence for the underlying neurocognitive mechanisms remains challenging. In this electroencephalographic (EEG) study, participants with ASC and matched controls were instructed to choose between two cognitive tasks in each trial, and to respond to the subsequently presented target stimulus according to their task choice. While doing so, we tracked the frontally distributed contingent negative variation (CNV) during the task preparation interval as a measure of intentional control, and the posteriorly measured P3 during the task execution interval to monitor the translation of intentions into actions. The results support the notion of intentional control difficulties in ASC, where the CNV was attenuated in the ASC group compared to the control group. Furthermore, the CNV was differentiated between the tasks and transition types in the control group only, suggesting that the ASC group was less fine-tuning the required amount of intentional control to contextual circumstances. In contrast, the P3 showed no significant differences between the groups. Together, these findings highlight the importance of intentional control mechanisms as a crucial future route for a better understanding of cognitive flexibility and behavioural rigidity in ASC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neuropsychologia.2018.07.008 | DOI Listing |
J Prev Alzheimers Dis
January 2025
Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. Electronic address:
Background: There are no approved oral disease-modifying treatments for Alzheimer's disease (AD).
Objectives: The objective of this study was to assess efficacy and safety of blarcamesine (ANAVEX®2-73), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) in early AD through restoration of cellular homeostasis including autophagy enhancement.
Design: ANAVEX2-73-AD-004 was a randomized, double-blind, placebo-controlled, 48-week Phase IIb/III trial.
BMJ Open
January 2025
Department of Intensive Care and Neonatology and Children's Research Center, University of Zurich, University Children's Hospital Zürich, Zurich, Zurich, Switzerland.
Introduction: Digital trials are a promising strategy to increase the evidence base for common interventions and may convey considerable efficiency benefits in trial conduct. Although paediatric intensive care units (PICUs) are rich in routine electronic data, highly pragmatic digital trials in this field remain scarce. There are unmet evidence needs for optimal mechanical ventilation modes in paediatric intensive care.
View Article and Find Full Text PDFLancet Infect Dis
January 2025
Department of Parasitology, Research and Training for Health Science, Université Iba Der Thiam de Thiès, Thiès, Senegal.
Background: In Africa, the scale-up of malaria-control interventions has reduced malaria burden, but progress towards elimination has stalled. Mass drug administration (MDA) is promising as a transmission-reducing strategy, but evidence from low-to-moderate transmission settings is needed. We aimed to assess the safety, coverage, and effect of three cycles of MDA with dihydroartemisinin-piperaquine plus single, low-dose primaquine on Plasmodium falciparum incidence and prevalence in southeast Senegal.
View Article and Find Full Text PDFBMC Public Health
January 2025
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Background: Compared to older adults with breast cancer (BC), adolescents and young adults (AYAs) develop more aggressive disease necessitating more intensive therapy with curative intent, which is disruptive to planned life trajectories. The burden of unmet needs among AYA BC survivors exists in two domains: (1) symptoms (e.g.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!